Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare neurological diseases in the United States. Its primary marketed product is WAKIX (pitolisant), a molecule with a novel mechanism of action approved for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company also has a robust pipeline, including pitolisant in Phase 3 clinical trials for Prader-Willi Syndrome, Phase 2 trials for Myotonic Dystrophy, and additional formulations such as Pitolisant Gastro-Resistant and Pitolisant High-Dose. Other pipeline candidates include BP1.15205, an orexin 2 receptor agonist for narcolepsy; HBS-102, a melanin-concentrating hormone receptor type 1 antagonist; ZYN-002 for Fragile X Syndrome and 22q Deletion Syndrome; EPX-100 for Dravet and Lennox-Gastaut syndromes; EPX-200 for developmental and epileptic encephalopathies; and CBS105 and CBS104 for treatment-resistant narcolepsy and refractory epilepsy, respectively.

Harmony Biosciences Holdings, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol HRMY. The company's financials are reported in US Dollars (USD), reflecting its operations based in the United States. As a US-based company trading on a major American exchange, its stock is traded in USD, making it accessible to investors through standard US brokerage accounts.

Harmony Biosciences operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching, developing, and commercializing innovative therapies for rare neurological diseases. The company's work involves advanced molecular science, including novel mechanisms of action such as pitolisant's targeting of histamine receptors, as well as orexin receptor agonists and serotonin receptor modulators. This places it at the intersection of pharmaceutical development and cutting-edge biotech research, addressing unmet medical needs in neurology.

Harmony Biosciences is headquartered in Plymouth Meeting, Pennsylvania, United States. The company primarily serves the US market, as indicated by its focus on commercializing therapies within the United States. Its marketed product WAKIX is available to adult patients with narcolepsy in the US, and its clinical trials for pipeline candidates are conducted in the US. The company's operations are centered on the American healthcare system, and it does not currently have a presence in international markets based on the available data.

Harmony Biosciences generates revenue primarily through the commercialization of its approved product, WAKIX (pitolisant), for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. As a commercial-stage pharmaceutical company, its business model involves developing therapies for rare neurological diseases, obtaining regulatory approval, and then marketing and selling these therapies to healthcare providers and patients in the United States. The company also invests in a diverse pipeline of drug candidates targeting conditions such as Prader-Willi Syndrome, Myotonic Dystrophy, Fragile X Syndrome, and various epileptic encephalopathies. If these candidates receive approval, they would contribute additional revenue streams. Harmony's focus on rare diseases allows it to address niche markets with high unmet medical needs, often benefiting from orphan drug designations and market exclusivity.